LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

Search

Ocular Therapeutix Inc

Ouvert

SecteurSoins de santé

12.4 0.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.09

Max

12.53

Chiffres clés

By Trading Economics

Revenu

-3.8M

-68M

Ventes

2.8M

13M

Marge bénéficiaire

-503.856

Employés

274

EBITDA

146K

-64M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+42.93% upside

Dividendes

By Dow Jones

Prochains Résultats

13 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

262M

2.2B

Ouverture précédente

11.75

Clôture précédente

12.4

Sentiment de l'Actualité

By Acuity

25%

75%

55 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Ocular Therapeutix Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2025, 23:01 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Résultats

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Résultats

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Acquisitions, Fusions, Rachats

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Acquisitions, Fusions, Rachats

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Résultats

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Résultats

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Résultats

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparaison

Variation de prix

Ocular Therapeutix Inc prévision

Objectif de Prix

By TipRanks

42.93% hausse

Prévisions sur 12 Mois

Moyen 17.78 USD  42.93%

Haut 21 USD

Bas 14 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

10

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

6.97 / 7.62Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

55 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat